NEO 250117 23.00C (NEO250117C23000) Stock Options, News & Quotes

US OptionsDetailed Quotes

NEO250117C23000

Watchlist

0.00
0.000.00%

15min DelayTrading Jan 24 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
Moomoo NewsJan 22 09:33 ET · Ratings
NeoGenomics: Strong Revenue Growth and Strategic Initiatives Underpin Buy Rating Amidst Management Changes
TipRanksJan 17 01:09 ET · Ratings
Benchmark Co. Maintains NeoGenomics(NEO.US) With Hold Rating
Moomoo NewsJan 16 08:33 ET · Ratings
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $19 to $19
Moomoo NewsJan 16 08:00 ET · Ratings
NeoGenomics: Balancing Promising Growth Prospects With Market Uncertainties and Valuation Concerns
TipRanksJan 15 20:18 ET
Express News | Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target
BenzingaJan 15 11:10 ET

Comments

Stock_Drift

Sep 23, 2024 18:24

$NeoGenomics (NEO.US)$

Stock_Drift

Sep 23, 2024 17:48

$NeoGenomics (NEO.US)$

Moomoo AI

Feb 29, 2024 07:27

The company's debt usage, EBIT loss, and liabilities exceeding cash and short-term receivables are worrisome. Its slow revenue growth and weak balance sheet position add to its perceived riskiness.

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Moomoo Recap US

Dec 28, 2023 15:06

Columns Wall Street Today | Stocks Advance, S&P Crawling Toward Record High

RECAP
U.S. stocks traded modestly higher Thursday, pushing the S&P 500 to within just a few points of a fresh record closing high.
The $S&P 500 Index (.SPX.US)$ gained 2 points, or 0.04%, to 4,783. The $Dow Jones Industrial Average (.DJI.US)$ rose by 53 points, or 0.14%, to 37,710. The $Nasdaq Composite Index (.IXIC.US)$ fell 4 points, or 0.03%, to 15,095.
U.S. stocks opened higher as the penultimate trading session of 2023 got un...

Moomoo AI

Dec 21, 2023 01:28

The company's high P/S ratio and future revenue predictions may not sustain the positive sentiment, putting shareholder investments and potential investors at risk of overpayment.

Getting In Cheap On NeoGenomics, Inc. (NASDAQ:NEO) Is Unlikely